Opendata, web and dolomites

MAGELIA SIGNED

A disruptive Magnetically Enhanced Library preparation platform for Next Generation Sequencing

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 MAGELIA project word cloud

Explore the words cloud of the MAGELIA project. It provides you a very rough idea of what is the project "MAGELIA" about.

company    succeed    curie    market    platforms    round    volumes    tool    2021    inception    ground    sequencing    modern    rights    medicine    trl6    automated    paris    awards    faster    confirmed    institut    medium    biological    raw    business    accelerate    pharmacy    advisory    entirely    ngs    magelia    struggle    samples    trl8    fast    exclusive    democratise    miniaturized    cnrs    series    1000    spin    seed    scarce    400    sme    team    platform    upstream    off    preparation    renowned    reagents    library    throughput    generation    leader    biology    expensive    board    preparations    clinicians    ignite    grants    reproducibility    genomics    smaller    talents    tackle    persons    france    labs    ten    accelerating    biologists    secured    companies    meet    initiate    first    instrument    billion    holds    earlier    prototype    ready    inorevia    cheaper    manual    revolution    won    turnover    15    leverages    larger    breaking    finish    backed    times    commercialization    microfluidics    scientists    2016    patents    miniaturised    biotech    put    engineers    customers   

Project "MAGELIA" data sheet

The following table provides information about the project.

Coordinator
INOREVIA 

Organization address
address: 6 RUE JEAN CALVIN
city: PARIS
postcode: 75005
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 2˙793˙000 €
 EC max contribution 1˙955˙100 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2021-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INOREVIA FR (PARIS) coordinator 1˙955˙100.00

Map

 Project objective

Inorevia is a spin-off from the Institut Curie/CNRS (Paris) that leverages over ten years of research in microfluidics to tackle challenges of modern Biology and Medicine with faster, cheaper, miniaturised sample preparation. Inorevia’s ground-breaking biology platform, the MAGELIA, will provide Biologists and Clinicians with a unique tool to efficiently process raw biological samples upstream of advanced analysis methods such as Next-Generation Sequencing (NGS) in volumes 100 to 1000 times smaller, in an entirely automated platform. After over 2 years of R&D and a first TRL6 prototype of the MAGELIA platform, Inorevia is ready to accelerate its development to reach TRL8, finish the development of the MAGELIA and initiate its commercialization by 2021. Aiming for the NGS sample preparation market, this first generation of the MAGELIA platform will meet the needs of low to medium throughput labs, sequencing platforms, biotech and pharmacy companies, who struggle with low-reproducibility manual library preparations, expensive reagents, and scarce biological samples. The MAGELIA platform will democratise NGS to ignite a revolution in genomics on a fast-growing 8 Billion € market. To succeed, Inorevia has put together an 8 persons’ team of recognized scientists, engineers, and confirmed business talents, backed by a renowned advisory board. The company holds exclusive rights on 4 key patents and large know-how. Since its inception in 2016, Inorevia has won several renowned awards in France and Europe, secured over 1.3 M€ in grants and a seed round. The MAGELIA SME Instrument Phase 2 project specifically aims at accelerating Inorevia’s go-to market through faster development, earlier pre-series and larger market reach in Europe. With the objective to reach over 400 customers and 15% of the European market within five years, with a turnover of 30 M€, INOREVIA will become the European leader in miniaturized samples preparation for modern biology and medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MAGELIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MAGELIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

MindTrack (2019)

Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders

Read More  

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More